View the latest Shaw & Partners Research Update for Cynata Therapeutics
Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating his “BUY” Rating
Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating his “BUY” Rating
Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation and raising his price target to $2.00
View the latest Shaw & Partners Research Update for Cynata Therapeutics